NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD)NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD)NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD)

NOVARTIS AG ADR-EACH REPR 1 CHF0.5(REGD)

No trades
See on Supercharts

Key facts today

Vyriad announced a strategic collaboration with Novartis to develop in vivo CAR-T cell therapies.
Novartis' CEO announced that the launch of the blood-cancer drug pelabresib, obtained from the Morphosys acquisition, could be postponed until 2027 or later due to the need for more safety data.
Analyze the impactAnalyze the impact
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪204.33 B‬USD
‪14.85 B‬USD
‪45.44 B‬USD
‪1.96 B‬
Beta (1Y)
0.37

About NOVARTIS N


CEO
Vasant Narasimhan
Headquarters
Basel
Founded
1996
FIGI
BBG00JVRG1Q6
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
‪0.00‬

See all ideas 

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Displays a symbol's price movements over previous years to identify recurring trends.
N
US66989HAS7
NOVARTIS CAP 20/50
Yield to maturity
6.37%
Maturity date
Aug 14, 2050
N
XPND
NOVARTIS CAPITAL 15/45
Yield to maturity
5.77%
Maturity date
Nov 20, 2045
N
NVS3904288
Novartis Capital Corp. 3.7% 21-SEP-2042
Yield to maturity
5.67%
Maturity date
Sep 21, 2042
N
US66989HAH1
NOVARTIS CAPITAL 14/44
Yield to maturity
5.61%
Maturity date
May 6, 2044
N
NVS5894401
Novartis Capital Corp. 4.7% 18-SEP-2054
Yield to maturity
5.49%
Maturity date
Sep 18, 2054
N
NVS5894400
Novartis Capital Corp. 4.2% 18-SEP-2034
Yield to maturity
5.12%
Maturity date
Sep 18, 2034
N
US66989HAR9
NOVARTIS CAP 20/30
Yield to maturity
4.95%
Maturity date
Aug 14, 2030
N
US66989HAP3
NOVARTIS CAP 20/25
Yield to maturity
4.92%
Maturity date
Feb 14, 2025
N
NVS5894399
Novartis Capital Corp. 4.0% 18-SEP-2031
Yield to maturity
4.86%
Maturity date
Sep 18, 2031
N
NVS5894398
Novartis Capital Corp. 3.8% 18-SEP-2029
Yield to maturity
4.67%
Maturity date
Sep 18, 2029
N
XPNC
NOVARTIS CAPITAL 15/25
Yield to maturity
4.63%
Maturity date
Nov 20, 2025

Explore more bonds